Home > Insider Trading > Filing (0001209191-17-064786)

Filing Details

Accession Number:: 0001209191-17-064786
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-12-08 17:27:16
Reporting Period:: 2017-12-06

Accepted Time:: 2017-12-08 17:27:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1652130	Intellia Therapeutics Inc.	NTLA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1377759	Nessan Bermingham	C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2017-12-06	99,033	$20.28	696,000	No	4	S	Direct
Common Stock	Disposition	2017-12-06	12,467	$20.84	683,533	No	4	S	Direct
Common Stock	Disposition	2017-12-07	103,574	$21.05	579,959	No	4	S	Direct
Common Stock	Disposition	2017-12-07	27,566	$21.46	552,393	No	4	S	Direct
Common Stock	Disposition	2017-12-08	94,143	$20.82	458,250	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $19.70 to $20.69. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.70 to $21.12. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.33 to $21.32. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $21.33 to $21.65. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.
The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.51 to $21.48. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price.